Targeted contrast agents for diagnostic and therapeutic use
First Claim
1. A method for providing an image of an internal region of a patient suffering from an arrhythmic disorder, wherein the method comprises (i) administering to the patient a contrast agent which comprises, in an aqueous carrier liposomes encapsulating a fluorinated gas and bearing a targeting ligand, wherein said targeting ligand targets cells or receptors associated with a coagulum and said fluorinated gas is selected from the group consisting of perfluorocarbons and sulfur hexafluoride;
- and (ii) scanning the patient using ultrasound to obtain a visible image of the region.
8 Assignments
0 Petitions
Accused Products
Abstract
Novel contrast agents which may be used for diagnostic and therapeutic use. The compositions may comprise a lipid, a protein, polymer and/or surfactant, and a gas, in combination with a targeting ligand. In preferred embodiments, the targeting ligand targets coagula, including emboli and/or thrombi, particularly in patients suffering from an arrhythmic disorder. The contrast media can be used in conjunction with diagnostic imaging, such as ultrasound, as well as therapeutic applications, such as therapeutic ultrasound.
-
Citations
174 Claims
-
1. A method for providing an image of an internal region of a patient suffering from an arrhythmic disorder, wherein the method comprises (i) administering to the patient a contrast agent which comprises, in an aqueous carrier liposomes encapsulating a fluorinated gas and bearing a targeting ligand, wherein said targeting ligand targets cells or receptors associated with a coagulum and said fluorinated gas is selected from the group consisting of perfluorocarbons and sulfur hexafluoride;
- and (ii) scanning the patient using ultrasound to obtain a visible image of the region.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 173)
-
56. A method for diagnosing the presence of a coagulum in a patient suffering from an arrhythmic disorder, wherein the method comprises (i) administering to the patient a contrast agent which comprises, in an aqueous carrier, liposomes having encapsulated therein a fluorinated gas, said liposomes bearing a targeting ligand, wherein said targeting ligand targets cells or receptors associated with a coagulum and said fluorinated gas is selected from the group consisting of perfluorocarbons and sulfur hexafluoride;
- and (ii) scanning the patient using ultrasound to obtain a visible image of any coagulum in the patient.
- View Dependent Claims (57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 174)
- 111. A composition for use in targeting an internal region of a patient suffering from an arrhythmic disorder, wherein the composition comprises liposomes encapsulating a fluorinated gas and bearing a targeting ligand, wherein said targeting ligand targets cells or receptors associated with a coagulum and said fluorinated gas is selected from the group consisting of perfluorocarbons and sulfur hexafluoride.
Specification
-
- Resources
-
Current AssigneeCerevast Medical, Inc.
-
Original AssigneeImarx Pharmaceutical Corp. (Sycamore Entertainment Group, Inc.)
-
InventorsFritz, Thomas A., Unger, Evan C., Gertz, Edward W.
-
Primary Examiner(s)Dees, Jose' G.
-
Assistant Examiner(s)Hartley, Michael G.
-
Application NumberUS08/932,273Time in Patent Office1,140 DaysField of Search424/9.52, 424/9.51, 424/9.5, 424/450, 424/812, 600/441, 600/458, 264/4.1, 427/2.14, 427/213.3, 428/402.2US Class Current424/9.52CPC Class CodesA61K 49/223 Microbubbles, hollow micros...A61K 49/227 Liposomes, lipoprotein vesi...A61K 49/228 Host-guest complexes, clath...B82Y 5/00 Nanobiotechnology or nanome...
